Radium (223Ra) dichloride (223RaCl2) is a radioactive compound of the element radium, with a half life of 11.43 days. It is used in cancer therapy as a source of alpha radiation. It is also used in nuclear medicine for diagnostics and therapy. As a pharmaceutical, it is used for the palliative treatment of bone pain caused by metastatic bone cancer. Radium dichloride can be administered either orally or intravenously. Radium dichloride is a white, crystalline, water-soluble solid. It is produced by the reaction of radium metal with chlorine gas. The resulting compound is highly radioactive and emits alpha particles and gamma rays. In addition to its medical applications, radium dichloride is also used in research for experiments involving radiation damage and for measuring radiation levels.
Radium-223 dichloride, also known by the brand name Xofigo, is a radioactive medication used to treat castration-resistant prostate cancer that has spread to the bones [1]. Here's a breakdown of its key features:
- Function: It works by mimicking calcium and targeting areas of increased bone turnover in bone metastases [1, 2]. Once localized, it emits alpha particles that damage cancer cells [2, 3].
- Benefits: Radium-223 dichloride helps with bone pain and reduces the risk of fractures in patients with metastatic bone cancer [2, 3].
- Safety: It's a radioactive drug and should only be handled by healthcare professionals trained in handling radioactive materials [1].
Important points to note:
- Radium-223 dichloride is not for everyone and has specific use cases. It should only be administered under the supervision of a qualified doctor [1].
- Due to its radioactive nature, there are potential side effects like nausea, vomiting, and fatigue [1].